Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference

Rhea-AI Summary

Anixa Biosciences, Inc. will present at the Ovarian Cancer National Conference to discuss the clinical development of its Phase 1 ovarian cancer CAR-T therapy. The conference is organized by the Ovarian Cancer Research Alliance, which has invested $100 million in research and advocated for $200 million in government funding.

Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial

SAN JOSE, Calif., Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 – 3, 2023.

The presentation, entitled "Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer - A Phase 1 Clinical Trial" will be presented by Dr. Pamela Garzone, Anixa's Chief Development Officer; and will discuss the clinical development of Anixa's novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

"We are pleased to be presenting at the Ovarian Cancer National Conference," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "We look forward to providing an overview of our Phase 1 ovarian cancer trial to an audience which is highly interested in new therapies to battle ovarian cancer."

The Ovarian Cancer National Conference is organized by the Ovarian Cancer Research Alliance ("OCRA"). OCRA is the leading organization in the world fighting ovarian cancer from all fronts while supporting women and their families. The organization has invested $100 million in ovarian cancer research, educated 95,000 medical professionals, and advocated for $200 million in government research and education funding.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contacts:
Stephen Kilmer
Investor Relations
skilmer@anixa.com
646-274-3580

Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-ovarian-cancer-research-alliance-ocra-ovarian-cancer-national-conference-301972345.html

SOURCE Anixa Biosciences, Inc.

FAQ

What is the name of the company presenting at the Ovarian Cancer National Conference?

The company presenting at the Ovarian Cancer National Conference is Anixa Biosciences, Inc.

What will be the topic of Anixa Biosciences' presentation?

The presentation will discuss the clinical development of Anixa's Phase 1 ovarian cancer CAR-T therapy.

Who will be presenting at the conference?

Dr. Pamela Garzone, Anixa's Chief Development Officer, will be presenting at the conference.

Who organized the Ovarian Cancer National Conference?

The Ovarian Cancer National Conference is organized by the Ovarian Cancer Research Alliance (OCRA).

How much has OCRA invested in ovarian cancer research?

OCRA has invested $100 million in ovarian cancer research.

What is the total amount of government research and education funding advocated by OCRA?

OCRA has advocated for $200 million in government research and education funding.